FOCUS ON GENOMICS, PROTEOMICS AND CLINICAL TRIALS
NOVEMBER 15-16, 2001
BETHESDA, MD
GENE EXPRESSION IN COMPLEX NEUROPSYCHIATRIC DISORDERS
Sabine Bahn, Cambridge University
MICROASSARY ANALYSIS OF THE STANLEY BRAIN COLLECTION
Pamela Sklar, Whitehead Institute
PRELIMIARY SCREENING OF GENE EXPRESSION IN SCHIZOPHRENIA
cDNA MICROARRAY
Marquis Vawter, University of California, Irvine
SCHIZOPHRENIA AS A DISEASE OF THE SYNAPSE
Karoly Mirnics, University of Pittsburgh
RNA PROFILING IN NEUROPSYCHIATRIC AND NEURODEGENERATIVE
DISORDERS
Allen Fienberg, Rockefeller University
TECHNOLOGIES AND STRATEGIES FOR STUDYING GENE EXPRESSION
CHANGES IN PSYCHIATRIC DISEASE
C. Anthony Altar, Psychiatric Genomics, Inc., Gaithersburg, MD
ASSEMBLY OF A NEUROPSYCHIATRIC cDNA ARRAY
Kevin Becker, National Institutes of Health
PROFILING THE BRAIN WITH MICROARRAYS: DATA ANALYSIS ISSUES
Simon Lin, Duke University
GENE EXPRESSION CHANGES FOLLOWING NEONATAL VENTRAL
HIPPOCAMPAL LESIONS
Graham Wood, Douglas Hospital Research Center, McGill University
THE HUMAN BRAIN PROTEOME: INITIAL RESULTS FROM THE HUMAN
PROTEIN INDEX PROJECT
N. Leigh Anderson, Large Scale Biology
PROTEINCHIP PROTEOMICS FOR PROFILING OF NEUROPSYCHIATRIC
DISEASE
Eric Fung, Ciphergen Biosystems
TRANSLATIONAL PERSPECTIVES ON THE RATIONALE AND
STRATEGIES FOR NOVEL DRUG DEVELOPMENT
Jeffrey Lieberman, University of North Carolina at Chapel Hill
POSSIBLE ROLE OF MYELIN RELATED GENES IN SCHIZOPHRENIA
Ken Davis, Mount Sinai School of Medicine
DEVELOPING MEDICATION STRATEGIES FOR RELAPSE PREVENTION IN
SCHIZOPHRENIA
John Kane, Hillside Hospital-A division of Long Island Jewish Medical Center
LOOKING ELSEWHERE: NEW TARGETS AND TREATMENTS FOR
BIPOLAR DISORDER
Bruce Cohen, McLean Hospital
PROSPECTS FOR NEW AND NOVEL THERAPEUTIC APPROACHES TO
MOOD AND ANXIETY DISORDERS
Dennis Charney, National Institute of Mental Health
TARGETS FOR DEVELOPMENT OF NOVEL ANTIDEPRESSANT AND MOOD
STABILIZER; GSK-3 AND NEUROTROPHIC FACTORS SIGNALING
CASCADES
Husseini Manji, National Institutes of Mental Health
IN VIVO BRAIN IMAGING AND DRUG DEVELOPMENT
Clinton Kilts, Emory University
ANTI-INFAMMATORY AGENTS FOR SCHIZOPHRENIA
Norbert Müller, Ludwig Maximilians Universität München, Germany
PHARMACO GENOMIC STRATEGIES FOR NEW DRUG DEVELOPMENT
Anil Malhotra, Hillside Hospital- A Division of Long Island Jewish Medical Center
RELEVANCE OF ANTIBIOTIC STUDIES TO ETIOLOGICAL HYPOTHESES
Robert Yolken, Stanley Division of Developmental Neurovirology, Johns Hopkins
University
STRATEGIES FOR SELECTING TARGETS FOR DRUG DEVELOPMENT IN
SCHIZOPHENIA
Carol Tamminga, Maryland Psychiatric Research Center, University of Maryland
REELING IN PSYCHOSIS
John Davis, University of Illinois at Chicago
COMPENSATORY PROCESSES MAINTAINING FUNCTION AFTER GENE
DELETION OF DA RECEPTOR SUBTYPE INDICATE NOVEL DRUG
TARGETS
John Waddington, Royal College of Surgeons in Ireland Medical School
POSTERS
PRELIMINARY EXAMINATION OF REGIONAL DISTRIBUTION OF HUMAN
CORONOVIRUS RNA IN POST MORTEM HUMAN BRAIN
Arlene Collins, State University of New York at Buffalo
PRELIMINARY EVALUATION OF VIRUSES AND INTRACELLULAR
BACTERIA STATUS IN URBAN CATS AND THEIR RELATIONSHIP WITH
DEVELOPMENT OF SCHIZOPHRENIA IN HUMANS
Reza Firouzi, Laboraiare des Deficits Immunitaires, France
CLONALLY EXPANDED T CELLS ARE PRESENT IN THE CSF OF PATIENTS
WITH MAJOR DEPRESSION
Emilia Oleszak, Temple University School of Medicine
MICROARRAY STUDIES – AN INTEGRATIVE PLATFORM FOR CASECONTROL STUDIES AND ANIMAL MODELS OF SCHIZOPHRENIA
Francois Feron, Queensland Center for Schizophrenia, Australia
ALTERED LEVELS OF REELIN AND ITS ISOFORMS IN SCHIZOPHRENIA
AND MOOD DISORDERS
S. H. Fatemi, University of Minnesota
TGF-BETAL EXPRESSION IN SUBJECTS WITH MOOD DISORDERS AND
LITHIUM-TREATED RATS
L. Trevor Young, McMasters University, Ontario
ON THE ROLE OF INFECTION IN SCHIZOPHRENIA AND OTHER MENTAL
ILLNESSES-HISTORICAL PERSPECTIVES AND THERAPEUTIC
IMPLICATIONS
S. H. Shakman, Institute of Science, California
DEVELOPMENT OF BROADLY AMPLIFYING REAL TIME PCRS FOR
DETECTION AND QUANTIFICAITON OF RETROVIRAL NUCLEIC ACID
Jonas Blomberg, Uppsala University, Sweden
GENOMIC DNA STABILITY AND SCHIZOPHRENIA IN TWINS
Cassandra L. Smith, Boston University
RETROVIRUS REACTIVITY OF PERINATAL SERA FROM MOTHERS
WHOSE CHILDREN DEVELOPED SCHIZOPHRENIA
Erik P. Lillehoj, University of Maryland
ARE HIGH TITERS OF ANTIBODIES AGAINST CYTOMEGALOVIRUS IN
SCHIZOPHRENIA ASSOCIATED WITH BETTER OUTCOME TO ANTIINFLAMMATORY THERAPY?
Norbert Müller, Ludwig Maximilians Universität München, Germany
TNF-ALPHA POLYMORPHISM G308A MAY PROJECT FROM
CYTOMEGALOVIRUS INFECTION IN SCHIZOPHRENIA
Norbert Müller, Ludwig Maximilians Universität München, Germany
DEFICIENT CALCIUM-DEPENDENT NITRIC OXIDE SYNTHASE ACTIVITY
IN THE PREFRONTAL CORTEX OF SCHIZOPHRENIA AND DEPRESSION
Guoqiang Xing, Psychology Department, USUHS, Bethesda, MD